IN2014MN01183A - - Google Patents
Info
- Publication number
- IN2014MN01183A IN2014MN01183A IN1183MUN2014A IN2014MN01183A IN 2014MN01183 A IN2014MN01183 A IN 2014MN01183A IN 1183MUN2014 A IN1183MUN2014 A IN 1183MUN2014A IN 2014MN01183 A IN2014MN01183 A IN 2014MN01183A
- Authority
- IN
- India
- Prior art keywords
- formula
- heteromultimers
- compounds
- mediated
- therapy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000004257 Potassium Channel Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108020001213 potassium channel Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1119703.5A GB201119703D0 (en) | 2011-11-15 | 2011-11-15 | Compounds |
GBGB1214250.1A GB201214250D0 (en) | 2012-08-09 | 2012-08-09 | Compounds |
PCT/GB2012/052842 WO2013072694A1 (en) | 2011-11-15 | 2012-11-15 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN01183A true IN2014MN01183A (pm) | 2015-07-03 |
Family
ID=47222145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1183MUN2014 IN2014MN01183A (pm) | 2011-11-15 | 2012-11-15 |
Country Status (15)
Country | Link |
---|---|
US (2) | US9290511B2 (pm) |
EP (1) | EP2780343A1 (pm) |
JP (1) | JP2014533259A (pm) |
KR (1) | KR20140094603A (pm) |
CN (1) | CN104011054B (pm) |
AR (1) | AR090037A1 (pm) |
AU (1) | AU2012338570A1 (pm) |
BR (1) | BR112014011671A2 (pm) |
CA (1) | CA2855346A1 (pm) |
IN (1) | IN2014MN01183A (pm) |
MX (1) | MX2014005935A (pm) |
RU (1) | RU2014124101A (pm) |
TW (1) | TWI498331B (pm) |
WO (1) | WO2013072694A1 (pm) |
ZA (1) | ZA201403503B (pm) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2914606C (en) | 2013-06-06 | 2021-03-23 | Astellas Pharma Inc. | Benzothiophene compound |
FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
RU2545758C1 (ru) * | 2014-03-20 | 2015-04-10 | Общество с ограниченной ответственностью "Алион" | Бициклические пиримидины или их фармацевтически приемлемые соли-активаторы антиоксидантной программы и их применение в качестве цитопротекторов |
US10246464B2 (en) | 2014-09-09 | 2019-04-02 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
AR104020A1 (es) | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
FR3037957B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037956B1 (fr) * | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037959B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037958B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
AU2016378723B2 (en) | 2015-12-22 | 2021-09-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
MX387806B (es) | 2016-03-16 | 2025-03-19 | Kura Oncology Inc | Inhibidores biciclicos con puente sustituidos de menina-mll y metodos de uso |
EP3429591B1 (en) * | 2016-03-16 | 2023-03-15 | Kura Oncology, Inc. | Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use |
CN106727587A (zh) * | 2016-11-28 | 2017-05-31 | 李娜 | 一种治疗心律失常的药物组合物 |
MX390582B (es) | 2016-12-28 | 2025-03-20 | Dart Neuroscience Llc Star | Compuestos de pirazolopirimidinona sustituida como inhibidores de fosfodiesterasas 2 (pde2) |
EA038388B1 (ru) * | 2017-01-16 | 2021-08-19 | Кура Онколоджи, Инк. | Замещенные ингибиторы менина-mll и способы применения |
CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
MX2019014875A (es) | 2017-06-21 | 2021-01-29 | SHY Therapeutics LLC | Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica. |
WO2019034603A1 (en) * | 2017-08-14 | 2019-02-21 | Acesion Pharma Aps | SUBSTITUTED BENZIMIDAZOLES USEFUL AS INHIBITORS OF THE POTASSIUM CHANNEL |
WO2019060365A1 (en) | 2017-09-20 | 2019-03-28 | Kura Oncology, Inc. | SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE |
ES2902365T3 (es) | 2017-11-27 | 2022-03-28 | Dart Neuroscience Llc | Compuestos de furanopirimidina sustituidos como inhibidores de PDE1 |
CN108117556A (zh) * | 2018-01-15 | 2018-06-05 | 王山川 | 一种细胞周期检查点激酶1抑制剂的合成方法 |
WO2020085493A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 新規なインダゾール化合物又はその塩 |
EP3898609A1 (en) | 2018-12-19 | 2021-10-27 | Shy Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
WO2020132384A1 (en) | 2018-12-21 | 2020-06-25 | Celgene Corporation | Thienopyridine inhibitors of ripk2 |
UA129778C2 (uk) | 2019-10-28 | 2025-07-30 | Мерк Шарп Енд Доум Елелсі | Низькомолекулярні інгібітори g12c-мутантного kras |
WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
WO2022194191A1 (en) * | 2021-03-16 | 2022-09-22 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of kras g12d |
WO2022204720A1 (en) * | 2021-03-26 | 2022-09-29 | Sumitomo Pharma Oncology, Inc. | (furopyrimidin-4-yl)piperazine compounds and uses thereof |
CN115006468B (zh) * | 2022-06-28 | 2023-06-06 | 西安外事学院 | 一种复方中草药生发液及制备方法 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4008726A1 (de) | 1990-03-19 | 1991-09-26 | Basf Ag | Thieno(2,3-d)pyrimidinderivate |
AU651337B2 (en) * | 1990-03-30 | 1994-07-21 | Dowelanco | Thienopyrimidine derivatives |
WO1998008845A1 (en) | 1996-08-27 | 1998-03-05 | Novartis Ag | Herbicidal s-substituted 1,2,4,6-thiatriazines |
WO2004011057A1 (en) | 1998-02-07 | 2004-02-05 | Advanced Cardiovascular Systems, Inc. | Perfusion dilatation catherer with expanded support coil |
JP2001097979A (ja) | 1999-07-28 | 2001-04-10 | Takeda Chem Ind Ltd | 縮合複素環化合物、その製造法および用途 |
HK1047106B (en) | 1999-09-17 | 2006-04-28 | Nissan Chemical Industries, Ltd. | Benzopyran derivative |
US6887870B1 (en) | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
SE9904738D0 (sv) | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
DE10031585A1 (de) * | 2000-06-29 | 2002-01-10 | Merck Patent Gmbh | 2-Aminoalkyl-thieno[2,3-d]pyrimidine |
TW589305B (en) | 2001-02-14 | 2004-06-01 | Nissan Chemical Ind Ltd | 4-aminobenzopyran derivatives |
KR100869897B1 (ko) | 2001-06-25 | 2008-11-24 | 닛산 가가쿠 고교 가부시키 가이샤 | 부정맥 치료용 치환 벤조피란 유도체 |
US7115741B2 (en) | 2001-09-06 | 2006-10-03 | Levy Daniel E | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds |
WO2003022852A2 (en) * | 2001-09-11 | 2003-03-20 | Smithkline Beecham Corporation | Furo-and thienopyrimidine derivatives as angiogenesis inhibitors |
US20040138238A1 (en) * | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
ES2217956B1 (es) * | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
US20050222175A1 (en) | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
GB0315950D0 (en) * | 2003-06-11 | 2003-08-13 | Xention Discovery Ltd | Compounds |
PL1641803T6 (pl) | 2003-06-11 | 2011-04-29 | Xention Ltd | Pochodne tienopirymidyny jako inhibitory kanału potasowego |
US7594219B2 (en) | 2003-07-24 | 2009-09-22 | International Business Machines Corporation | Method and apparatus for monitoring compatibility of software combinations |
TWI346112B (en) | 2004-02-25 | 2011-08-01 | Nissan Chemical Ind Ltd | Benzopyran compound |
MXPA06011799A (es) * | 2004-04-12 | 2006-12-15 | Sankyo Co | Derivados de tienopiridina. |
WO2005121149A1 (en) | 2004-06-10 | 2005-12-22 | Xention Discovery Limited | Furanopyrimidine compounds effective as potassium channel inhibitors |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
US8008487B2 (en) | 2004-10-21 | 2011-08-30 | Dow Agrosciences Llc | Substituted thieno[2,3-D]pyrimidines as fungicides |
US7576212B2 (en) * | 2004-12-09 | 2009-08-18 | Xention Limited | Thieno[2,3-B] pyridines as potassium channel inhibitors |
EP1879899B1 (en) * | 2004-12-09 | 2010-08-04 | Xention Limited | Thienopyridine derivatives as potassium channel inhibitors |
US7576080B2 (en) | 2004-12-23 | 2009-08-18 | Memory Pharmaceuticals Corporation | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
WO2006079916A1 (en) | 2005-01-26 | 2006-08-03 | Pharmacia & Upjohn Company Llc | Thieno [2,3-d] pyrimidine compounds as inhibitors of adp-mediated platelets aggregation |
CA2602358A1 (en) | 2005-03-25 | 2006-09-28 | Pharmacia & Upjohn Company Llc | 4-piperazinnylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors |
EP1866317A1 (en) | 2005-03-28 | 2007-12-19 | Pharmacia & Upjohn Company LLC | 4-piperazinothieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors |
JP2008534570A (ja) | 2005-03-28 | 2008-08-28 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 血小板凝集阻害薬としての4−ピペラジニルチエノ[2,3−d]ピリミジン化合物 |
US20080194590A1 (en) | 2005-03-28 | 2008-08-14 | Pfizer Inc | 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors |
US20060281768A1 (en) * | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
US20100143341A1 (en) * | 2005-06-22 | 2010-06-10 | Develogen Aktiengesellschaft | Thienopyrimidines for pharmaceutical compositions |
AU2005336552B2 (en) * | 2005-09-23 | 2010-09-16 | Equispharm Co., Ltd | 5,6-dimethylthieno(2,3-di) pyrimidine derivatives, the preparation method thereof and the pharmaceutical composition comprising the same for anti-virus |
WO2007056214A2 (en) * | 2005-11-02 | 2007-05-18 | Cytovia, Inc | N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof |
GB0525164D0 (en) | 2005-12-09 | 2006-01-18 | Xention Discovery Ltd | Compounds |
EA200802118A1 (ru) * | 2006-04-07 | 2009-04-28 | Девелоджен Ациенгезельшафт | Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях |
JP2009539988A (ja) | 2006-06-12 | 2009-11-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルの調節因子として有用なチエノピリミジン |
DE102006030236A1 (de) | 2006-06-30 | 2008-01-03 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Direktoxidationsbrennstoffzelle für den konvektionsfreien Transport des Brennstoffs und Verfahren zum Betreiben der Brennstoffzelle |
EP1947103A1 (en) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
GB0713602D0 (en) | 2007-07-12 | 2007-08-22 | Syngenta Participations Ag | Chemical compounds |
CA2705719C (en) * | 2007-09-14 | 2016-10-11 | Janssen Pharmaceutica N.V. | Thieno-and furo-pyrimidine modulators of the histamine h4 receptor |
CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
PL2254873T3 (pl) | 2008-02-22 | 2014-10-31 | Otsuka Pharma Co Ltd | Związek benzodiazepinowy i kompozycja farmaceutyczna |
US20100227853A1 (en) | 2008-04-18 | 2010-09-09 | Trustees Of Boston College | Inhibitors of cyclic amp phosphodiesterases |
US7863291B2 (en) | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
US8486953B2 (en) * | 2008-08-26 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Thienopyrimidines for pharmaceutical compositions |
TWI334124B (en) * | 2008-08-28 | 2010-12-01 | Au Optronics Corp | Display drive circuit for flat panel display and driving method for gate lines |
TWI389913B (zh) | 2008-09-08 | 2013-03-21 | Lg Life Sciences Ltd | 并合雜環化合物 |
KR20110092267A (ko) | 2008-09-10 | 2011-08-17 | 칼립시스, 인코포레이티드 | 질환의 치료를 위한 히스타민 수용체의 아미노피리미딘 억제제 |
WO2010033127A1 (en) | 2008-09-22 | 2010-03-25 | Sionyx, Inc. | Response-enhanced monolithic-hybrid pixel |
CA2773131C (en) | 2009-09-04 | 2015-07-14 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
NZ600240A (en) | 2009-10-29 | 2014-04-30 | Bristol Myers Squibb Co | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
CA2788450A1 (en) | 2009-12-30 | 2011-07-07 | Arqule, Inc. | Substituted naphthalenyl-pyrimidine compounds |
TW201219401A (en) * | 2010-09-14 | 2012-05-16 | Lexicon Pharmaceuticals Inc | Bicyclic inhibitors of Notum Pectinacetylesterase and methods of their use |
EP2651404B1 (en) | 2010-12-14 | 2015-10-14 | Electrophoretics Limited | Casein kinase 1delta (ck1delta) inhibitors |
EP3239154A1 (en) | 2011-01-10 | 2017-11-01 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
-
2012
- 2012-11-14 AR ARP120104296A patent/AR090037A1/es unknown
- 2012-11-15 TW TW101142693A patent/TWI498331B/zh not_active IP Right Cessation
- 2012-11-15 MX MX2014005935A patent/MX2014005935A/es not_active Application Discontinuation
- 2012-11-15 JP JP2014540560A patent/JP2014533259A/ja active Pending
- 2012-11-15 RU RU2014124101/04A patent/RU2014124101A/ru not_active Application Discontinuation
- 2012-11-15 CN CN201280061286.3A patent/CN104011054B/zh not_active Expired - Fee Related
- 2012-11-15 BR BR112014011671A patent/BR112014011671A2/pt not_active IP Right Cessation
- 2012-11-15 AU AU2012338570A patent/AU2012338570A1/en not_active Abandoned
- 2012-11-15 CA CA2855346A patent/CA2855346A1/en not_active Abandoned
- 2012-11-15 EP EP12790948.9A patent/EP2780343A1/en not_active Withdrawn
- 2012-11-15 KR KR1020147015757A patent/KR20140094603A/ko not_active Withdrawn
- 2012-11-15 US US14/358,722 patent/US9290511B2/en not_active Expired - Fee Related
- 2012-11-15 WO PCT/GB2012/052842 patent/WO2013072694A1/en active Application Filing
- 2012-11-15 IN IN1183MUN2014 patent/IN2014MN01183A/en unknown
-
2014
- 2014-05-14 ZA ZA2014/03503A patent/ZA201403503B/en unknown
-
2016
- 2016-02-05 US US15/016,846 patent/US20160152634A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN104011054B (zh) | 2016-08-24 |
AR090037A1 (es) | 2014-10-15 |
US9290511B2 (en) | 2016-03-22 |
RU2014124101A (ru) | 2015-12-27 |
CA2855346A1 (en) | 2013-05-23 |
WO2013072694A1 (en) | 2013-05-23 |
ZA201403503B (en) | 2016-09-28 |
KR20140094603A (ko) | 2014-07-30 |
US20160152634A1 (en) | 2016-06-02 |
TWI498331B (zh) | 2015-09-01 |
NZ626199A (en) | 2015-04-24 |
EP2780343A1 (en) | 2014-09-24 |
JP2014533259A (ja) | 2014-12-11 |
BR112014011671A2 (pt) | 2017-05-30 |
CN104011054A (zh) | 2014-08-27 |
TW201326178A (zh) | 2013-07-01 |
MX2014005935A (es) | 2014-09-04 |
US20140371203A1 (en) | 2014-12-18 |
AU2012338570A1 (en) | 2014-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN01183A (pm) | ||
IN2012DN00971A (pm) | ||
MX362550B (es) | Inhibidores ciclicos de glutaminasa. | |
IN2014KN00769A (pm) | ||
TN2012000465A1 (en) | Derivatives of 1-amino-2-cyclopropylethylboronic acid | |
MX343534B (es) | Inhibidores de arginasa y sus aplicaciones terapeuticas. | |
MD20150043A2 (ro) | Inhibitori ai histon-demetilazelor | |
AU2012214029A8 (en) | Rorgammat inhibitors | |
ZA201606320B (en) | Human plasma kallikrein inhibitors | |
IN2014DN10670A (pm) | ||
IN2014CN04907A (pm) | ||
IN2014MN00988A (pm) | ||
MX2020001602A (es) | Inhibidor del antigeno-1 asociado a la funcion del linfocito (lfa-1) y polimorfo del mismo. | |
MX2012003644A (es) | Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila. | |
MY172924A (en) | Neprilysin inhibitors | |
SG10201811204RA (en) | Bicyclic heterocyclyl derivatives as irak4 inhibitors | |
MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
MX2013008192A (es) | Inhibidores de bace-2 para tratamiento de transtornos metabolicos. | |
JO2998B1 (ar) | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان | |
IN2014CN04676A (pm) | ||
IN2014MN00948A (pm) | ||
GEP20146125B (en) | Aminopyrimidines as syk inhibitors | |
UA118610C2 (uk) | Спіроциклічні інгібітори катепсину c | |
EA201291099A1 (ru) | Новые иммуномодуляторные и противовоспалительные соединения | |
GEP20135964B (en) | Inhibitors of beta-secretase |